A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.

[1]  L. Read,et al.  A milk growth factor extract reduces chemotherapeutic drug toxicity in epithelial cells in vitro , 2001, In Vitro Cellular & Developmental Biology - Animal.

[2]  M. Rogers,et al.  Milk-derived growth factors as serum supplements for the growth of fibroblast and epithelial cells , 1995, In Vitro Cellular & Developmental Biology - Animal.

[3]  T. Shea,et al.  Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .

[4]  D. Howard,et al.  Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  T. Fleming,et al.  A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. , 2004, Leukemia research.

[6]  D. McGuire,et al.  Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis , 2004, Cancer.

[7]  J. Rossi,et al.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies , 2004, Cancer Chemotherapy and Pharmacology.

[8]  H. Lazarus,et al.  Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment , 2003, Bone Marrow Transplantation.

[9]  J. Clarke,et al.  Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. , 2002, Oral oncology.

[10]  H. Prince,et al.  High‐dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience , 2001, Internal medicine journal.

[11]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Jantunen,et al.  Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (⩾60 years) with non-Hodgkin’s lymphoma: comparison with patients <60 years treated within the same protocol , 2000, Bone Marrow Transplantation.

[13]  A. Cowin,et al.  Mitogenic whey extract stimulates wound repair activity in vitro and promotes healing of rat incisional wounds. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  A. Argiris,et al.  High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Ueno,et al.  Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Belford,et al.  New therapeutics from a dairy byproduct—Cheese whey , 1999 .

[17]  D. Zelterman,et al.  Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option , 1999, Bone Marrow Transplantation.

[18]  C. Payne,et al.  Platelet-derived growth factor, insulin-like growth factors, fibroblast growth factors and transforming growth factor beta do not account for the cell growth activity present in bovine milk. , 1997, The Journal of endocrinology.

[19]  R. Byard,et al.  Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. , 1996, The Journal of nutrition.

[20]  M. Rogers,et al.  Transforming growth factor beta in bovine milk: concentration, stability and molecular mass forms. , 1996, The Journal of endocrinology.

[21]  F. Ballard,et al.  Extraction from cheese whey by cation-exchange chromatography of factors that stimulate the growth of mammalian cells. , 1995, Journal of dairy science.

[22]  J. Strang,et al.  Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. , 1995, Leukemia & lymphoma.

[23]  K. Furuse.  [Phase III study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[24]  D C Linch,et al.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Sonis,et al.  A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients , 1993, Cancer.

[26]  R. Chopra,et al.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.

[27]  D. Linch,et al.  Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease , 1992, British journal of haematology.

[28]  A. Berger,et al.  Development, testing, and application of the oral assessment guide. , 1988, Oncology nursing forum.

[29]  P. Brunell,et al.  Anti-bovine antibody in human sera as a cause of nonspecificity in enzyme immunoassay , 1987, Journal of clinical microbiology.